Gyre Therapeutics

Gyre Therapeutics is a leading commercial-stage biotechnology company dedicated to developing innovative anti-fibrotic therapeutics for a range of chronic organ diseases. With a strong focus on research, development, and commercialization, Gyre Therapeutics is committed to addressing unmet medical needs and improving patient outcomes. Gyre Therapeutics is headquartered in San Diego, CA, at 12770 High Bluff Drive, Suite 150, San Diego, CA 92130, US.

Gyre Therapeutics has successfully brought ETUARY® from research to commercialization, reinvesting sales to fuel the company's clinical development pipeline. The company's lead compound, F351, a derivative of ETUARY® (Pirfenidone), has received breakthrough therapy designation for chronic HBV-associated liver fibrosis. Gyre Therapeutics is conducting a phase 3 confirmative clinical study based on phase 2 POC clinical data. Additionally, a F351 phase I study has been completed in the US, and an IND for a phase 2 clinical study for the treatment of NASH-associated fibrosis in the U.S. is planned for 2024.

Through its indirect controlling interest in Gyre Pharmaceuticals, Gyre Therapeutics is also advancing a diverse pipeline, including ETUARY therapeutic expansions, F573, F528, and F230. Gyre Therapeutics is poised for continued growth and innovation in the biotechnology sector. We invite the management team at Gyre Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further enhance their market presence.